Chest
-
Slide PresentationPRESENTED ON: Monday, March 24, 2014 at 10:45 AM - 11:45 AMPURPOSE: Hookah is a tobacco smoking tool which is thought to be harmless than cigarette, and there is no adequate studies about its hazards to health, that is threatening the youth of the world today. In this study, we aimed to indicate the accumulated carbon monoxide levels in breath, examine the changes in respiratory function tests and indicate the effect of the parameters of oxidative stres in blood after smooking hookah. ⋯ The following authors have nothing to disclose: Funda Karaduman Yalcin, Mukremin Er, Aysegul Senturk, Hatice Kilic, Hatice Canan HasanogluNo Product/Research Disclosure Information.
-
COPD PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: The aim of our study was to look for the factors that affect survival of patients with COPD exacerbations admitted in a pulmonology department of a Portuguese central hospital. ⋯ The following authors have nothing to disclose: Daniel Coutinho, Inês Franco, Margarida Dias, Maria Tzer, Maria BritoNo Product/Research Disclosure Information.
-
Tuberculosis PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: Tuberculosis (TB) remains a major health concern worldwide. Studies have shown an association between TB and venous thromboembolism (VTE); however, the significance of this association has not been investigated. Despite the increased risk of VTE among patients with TB, to our knowledge, the significance of in-hospital VTE in these patients has not been investigated. We sought to compare the risk factors profile and in-hospital outcomes of hospitalized patients with TB who had coexisting in-hospital VTE versus those who did not have coexisting VTE. ⋯ The following authors have nothing to disclose: Ahmadreza Moradi, Azin Mohebi-Nejad, Seyed-Mohammad Abooturabi, Behzad Yaghoubi, Shahrzad Shemirani, Payam Tabarsi, Neda Behzadnia, Mehdi Esmaili-Khansari, Mohammadreza Masjedi, Ehsan Chitsaz, Behnood Bikdeli, Babak Sharif-KashaniNo Product/Research Disclosure Information.
-
Interstitial Lung Disease CasesSESSION TYPE: Case ReportsPRESENTED ON: Saturday, March 22, 2014 at 09:00 AM - 10:00 AMINTRODUCTION: The course of adult Pulmonary Langerhans cell Histiocytosis (PLCH) is variable and unpredictable [1]. Conventional therapy is mainly based on smoking cessation. If the patient is severely symptomatic or the disease shows radiological or physiological deterioration after a short observation period, a course of steroids should be given. Chemotherapeutic drugs,like 2-chlorodeoxyadenosine, may be effective in childhood forms of disseminated LCH, but there is far too little experience with these agents in adult pulmonary LCH patient [1]. ⋯ The following authors have nothing to disclose: Juan Cruz Rueda, Julián Ceballos Gutiérrez, Ana Fulgencio, Jose Manuel Gonzalez de Vega, Ana Dolores Romero OrtizNo Product/Research Disclosure Information.
-
COPD QVA149 PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: Combined use of long-acting bronchodilators with different mechanism of action optimizes bronchodilation and may reduce the risk of exacerbations. QVA149 is a novel dual bronchodilator containing a fixed-dose combination of the long-acting β2-agonist (LABA) indacaterol and long-acting muscarinic antagonist (LAMA) glycopyrronium (NVA237) for the maintenance treatment of COPD. Here, we report findings from the SPARK and ILLUMINATE studies of the IGNITE program, with a focus on the rate and prevention of exacerbations. ⋯ Donald Banerji: Employee: Novartis Employee Mark Fedele: Employee: Novartis Employee Hungta Chen: Employee: Novartis EmployeeClinical trial results of QVA149, combination of approved products indacaterol and glycopyrronium, will be presented, QVA149 is in the late stage phase 3 trials prior to approval.